Therapeutic effect of granulocyte colony-stimulating factor and cephem antibiotics against experimental infections in neutropenic mice induced by cyclophosphamide.
Effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) against severe infections in cyclophosphamide (CY)-induced neutropenic mice were investigated by its single use or by its combination with cephem antibiotics. Treatment with rhG-CSF increased the number of peripheral blood leucocytes and strikingly shortened the duration of the neutropenic state. Most of the regained population in the peripheral blood leucocytes were neutrophils. Functions of neutrophils, such as phagocytic activity, superoxide release, and expression of Mac-1 molecules, were remarkably enhanced by administration of rhG-CSF. When rhG-CSF was administered to CY-induced neutropenic mice before infection, protective effects against various kinds of bacteria were remarkable. On the other hand, such remarkable effects were not observed when rhG-CSF was administered after infections. However, even in the case of post-infectious treatment, a combination therapy of rhG-CSF with cephem antibiotics, particularly with Cefodizime (CDZM), showed a significant improvement in the survival rate and a decrease in the number of viable bacteria in the liver. These results suggest that a combination therapy of rhG-CSF with cephem antibiotics, especially with CDZM, is an efficient regime against severe infections in patients with neutropenia induced by a heavy anti-tumour chemotherapy.
Wakiyama
H
H
Department of Microbiology, National Defense Medical College, Saitama, Japan.
Tsuru
S
S
Hata
N
N
Shinomiya
M
M
Shinomiya
N
N
Noritake
M
M
Umezawa
Y
Y
Rokutanda
M
M
D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy*; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003520:Cyclophosphamide; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D007958:Leukocyte Count / Q000187:drug effects; D016177:Macrophage-1 Antigen / Q000032:analysis; D051379:Mice; D008813:Mice, Inbred ICR; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy*; D009504:Neutrophils / Q000276:immunology; D010587:Phagocytosis; D011994:Recombinant Proteins / Q000008:administration & dosage; D016897:Respiratory Burst
D016177:Macrophage-1 Antigen; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D002439:Cefotaxime; C033356:cefodizime